Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338450 | 1.00 | ALDH1A1 (0.66) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL14725009 | 1.00 | ALDH1A1 (0.66) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL1313958 | 0.92 | ALDH1A1 (0.60) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL6976869 | 0.92 | ALDH1A1 (0.69) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL510895 | 0.92 | ALDH1A1 (0.69) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL12593016 | 0.92 | ALDH1A1 (0.69) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL6976500 | 0.87 | ALDH1A1 (0.64) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL12593023 | 0.86 | ALDH1A1 (0.62) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL510407 | 0.86 | ALDH1A1 (0.62) | ALDH1A1TLR7LMNATHRBSMN1; SMN2 | |
| SCHEMBL6973892 | 0.85 | TLR7 (0.50) | ALDH1A1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2561872-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-1824482-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | HAVCR2, IFNG, TPMT | ALDH1A1 273/4885TLR7 11/4885LMNA 4643/4885 |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | TLR5, THPO, IDO1 | ALDH1A1 340/4885TLR7 8/4885LMNA 4553/4885 |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | ALDH1A1 340/4885TLR7 8/4885LMNA 4553/4885 |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | ALDH1A1 340/4885TLR7 8/4885LMNA 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.